Key facts
- CORXEL Pharmaceuticals’s last known valuation is $474.9M (Sep 2024).
- It has raised $451.8M across 1 recorded rounds; the latest was Later Stage VC (Series D1) ($287.0M) in Jan 2026.
- Notable investors include RA Capital Management, New Enterprise Associates, The Invus Group, SR One Capital Management, RTW Investments — 13 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for CORXEL Pharmaceuticals
Funding rounds
1 roundsAbout CORXEL Pharmaceuticals
Developer of small molecule cardiac myosin inhibitor drug treatments designed for the treatment of hypertrophic cardiomyopathy, in-licensed from Cytokinetics. The company offers first-class treatments to Chinese cardiovascular and ophthalmology patients and treats patients suffering from serious life-threatening health diseases, thereby enabling biotechnology companies to respond to unmet medical needs in the fields of cardiovascular and ophthalmology diseases.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2019
- Employees
- 45
- Website
- corxelbio.com/
- Ownership
- Privately Held (backing)
CORXEL Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CORXEL Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CORXEL Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.